Abstract
Coronavirus Disease 2019 (COVID-19) is a global pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While detection of SARS-CoV-2 by polymerase chain reaction with reverse transcription (RT-PCR) is currently used to diagnose acute COVID-19 infection, serological assays are needed to study the humoral immune response to SARS-CoV-2. SARS-CoV-2 IgG/A/M antibodies against SARS-CoV-2 spike (S) protein and its receptor-binding domain (RBD) were characterized using an enzyme-linked immunosorbent assay (ELISA) and assessed for their ability to neutralize live SARS-CoV-2 virus in recovered subjects who were RT-PCR-positive (n=153), RT-PCR-negative (n=55), and control samples collected pre-COVID-19 (n=520). Anti-SARS-CoV-2 antibodies were detected in 90.9% of resolved subjects up to 180 days post-symptom onset. Anti-S protein and anti-RBD IgG titers correlated (r= 0.5157 and r = 0.6010, respectively) with viral neutralization. Of the RT-PCR-positive subjects, 22 (14.3%) did not have anti-SARS-CoV-2 antibodies; and of those, 17 had RT-PCR cycle threshold (Ct) values >27, raising the possibility that these indeterminate results are from individuals who were not infected, or had mild infection that failed to elicit an antibody response. This study highlights the importance of serological surveys to determine population-level immunity based on infection numbers as determined by RT-PCR.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding support for this work was provided by grants from the Ontario Research Fund (ORF), COVID-19 Rapid Research Fund (#C-191-2426729-NAZY) and by the Canadian Institute of Health Research (CIHR)-COVID-19 Immunity Task Force (CITF; #VR2-173204) awarded to Dr. Ishac Nazy, and Academic Health Sciences Organization (HAHSO) grant awarded to Dr. Don-ald M. Arnold (#HAH-21-02). This work was also supported, in part, by a Weston Family Microbiome Initiative Grant and a CIHR COVID-19 Rapid Response grant to Dr. Matthew S. Miller. Dr. Miller was also supported, in part, by a CIHR New Investigator Award and an Ontario Early Researcher Award. Ali Zhang is supported by a PSI Research Trainee Fellowship and a CIHR Canada Graduate Scholarships - Doctoral Award. Hannah D. Stacey was supported in part by an Ontario Graduate Scholarship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Hamilton Integrated Research Ethics Board (HIREB) and informed written consent was obtained from all participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Added cross-sectional study data. Increased number in populations.
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article.
